Moderna (MRNA) Stock Forecast & Price Target

Compare

17,748 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRNA Analyst Ratings

Hold

3 Buy

13 Hold

4 Sell

Based on 20 analysts giving stock ratings to

Moderna

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRNA Stock 12 Month Forecast

Average Price Target

$40.06

▲(64.65% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $40.06 with a high forecast of $198.00 and a low forecast of $12.00. The average price target represents a 64.65% change from the last price of $24.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","58":"$58","105":"$105","152":"$152","199":"$199"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":198,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$198.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,58,105,152,199],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.16,40.30153846153846,53.44307692307692,66.58461538461539,79.72615384615385,92.86769230769231,106.00923076923077,119.15076923076923,132.2923076923077,145.43384615384616,158.57538461538462,171.71692307692308,184.85846153846154,{"y":198,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.16,28.152307692307694,29.144615384615385,30.13692307692308,31.12923076923077,32.121538461538464,33.113846153846154,34.106153846153845,35.09846153846154,36.09076923076923,37.08307692307692,38.07538461538462,39.06769230769231,{"y":40.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.16,25.993846153846153,24.82769230769231,23.661538461538463,22.495384615384616,21.32923076923077,20.163076923076922,18.99692307692308,17.83076923076923,16.664615384615384,15.49846153846154,14.332307692307694,13.166153846153847,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.26,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.58,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.42,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":30.96,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.16,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.03,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.05,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.69,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.19,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$198.00

Average Price Target$40.06

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cory Kasimov

Evercore ISI

$28

Hold

15.08%

Upside

Reiterated

11/07/25

Evercore ISI Reaffirms Their Hold Rating on Moderna (MRNA)

Terence Flynn

Morgan Stanley

$32→$30

Hold

23.30%

Upside

Reiterated

11/07/25

Moderna price target lowered to $30 from $32 at Morgan StanleyModerna price target lowered to $30 from $32 at Morgan Stanley

Gena Wang

Barclays

$31→$25

Hold

2.75%

Upside

Reiterated

11/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Natera (NASDAQ: NTRA), Moderna (NASDAQ: MRNA) and Lifecore Biomedical (NASDAQ: LFCR)

Edward Tenthoff

Piper Sandler

$69

Buy

183.60%

Upside

Reiterated

11/07/25

Piper Sandler Remains a Buy on Moderna (MRNA)

Myles Minter

William Blair

―

Hold

―

Reiterated

11/06/25

Moderna's Strategic Challenges and Opportunities: A Hold Rating Amid Mixed Product Results and Market UncertaintiesWe highlight updated company guidance in exhibit 2 as well as our model updates in exhibit 3.

Joseph Stringer

Needham

―

Hold

―

Reiterated

11/06/25

Cautious Hold on Moderna: Awaiting Financial Stability Amid Revenue Shortfall and Promising Oncology DevelopmentsWe believe MRNA's vaccine franchise (COVID, Flu, etc.) could still produce ~$1.0B annually through 2030, with potential modest revenue upside from the rare disease pipeline, but not yet enough to offset OpEx. The oncology pipeline has begun producing incrementally positive data in combination with Keytruda, but we remain on the sidelines until more fulsome data from the oncology programs read out in 2026+.

Luca Issi

RBC Capital

$28

Hold

15.08%

Upside

Reiterated

11/06/25

Analysts Are Neutral on Top Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), Moderna (MRNA)

Harry Gillis

Berenberg Bank

$30

Hold

23.30%

Upside

Reiterated

10/31/25

Berenberg Bank Reaffirms Their Hold Rating on Moderna (MRNA)

Courtney Breen

Bernstein

$28→$25

Hold

2.75%

Upside

Reiterated

10/27/25

Bernstein Sticks to Its Hold Rating for Moderna (MRNA)

Tim Anderson

Bank of America Securities

$24

Sell

-1.36%

Downside

Reiterated

10/23/25

Moderna's Financial Challenges: Declining Vaccine Sales and High Cash Burn Rate Lead to Sell Rating

Jessica Fye

J.P. Morgan

$25

Sell

2.75%

Upside

Reiterated

10/23/25

J.P. Morgan Keeps Their Sell Rating on Moderna (MRNA)

Tyler Van Buren

TD Cowen

$25

Hold

2.75%

Upside

Reiterated

10/23/25

TD Cowen Remains a Hold on Moderna (MRNA)with no changes to our $25 price target and Hold (2) rating.

Geoff Meacham

Citi

$30→$28

Hold

15.08%

Upside

Reiterated

10/23/25

Moderna's Hold Rating: Impact of CMVictory Study and Vaccine Program Risks

Mani Foroohar

Leerink Partners

$16→$12

Sell

-50.68%

Downside

Reiterated

10/23/25

Moderna (MRNA) Receives a Sell from Leerink PartnersWe reduce our PT to $12 (from $16) and reiterate an Underperform rating.

David Dai

UBS

$40

Buy

64.41%

Upside

Reiterated

10/23/25

Optimistic Outlook on Moderna's Oncology Pipeline Amid CMV Setbacks: Buy Rating Reiterated

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cory Kasimov

Evercore ISI

$28

Hold

15.08%

Upside

Reiterated

11/07/25

Evercore ISI Reaffirms Their Hold Rating on Moderna (MRNA)

Terence Flynn

Morgan Stanley

$32→$30

Hold

23.30%

Upside

Reiterated

11/07/25

Moderna price target lowered to $30 from $32 at Morgan StanleyModerna price target lowered to $30 from $32 at Morgan Stanley

Gena Wang

Barclays

$31→$25

Hold

2.75%

Upside

Reiterated

11/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Natera (NASDAQ: NTRA), Moderna (NASDAQ: MRNA) and Lifecore Biomedical (NASDAQ: LFCR)

Edward Tenthoff

Piper Sandler

$69

Buy

183.60%

Upside

Reiterated

11/07/25

Piper Sandler Remains a Buy on Moderna (MRNA)

Myles Minter

William Blair

―

Hold

―

Reiterated

11/06/25

Joseph Stringer

Needham

―

Hold

―

Reiterated

11/06/25

Luca Issi

RBC Capital

$28

Hold

15.08%

Upside

Reiterated

11/06/25

Analysts Are Neutral on Top Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), Moderna (MRNA)

Harry Gillis

Berenberg Bank

$30

Hold

23.30%

Upside

Reiterated

10/31/25

Berenberg Bank Reaffirms Their Hold Rating on Moderna (MRNA)

Courtney Breen

Bernstein

$28→$25

Hold

2.75%

Upside

Reiterated

10/27/25

Bernstein Sticks to Its Hold Rating for Moderna (MRNA)

Tim Anderson

Bank of America Securities

$24

Sell

-1.36%

Downside

Reiterated

10/23/25

Moderna's Financial Challenges: Declining Vaccine Sales and High Cash Burn Rate Lead to Sell Rating

Jessica Fye

J.P. Morgan

$25

Sell

2.75%

Upside

Reiterated

10/23/25

J.P. Morgan Keeps Their Sell Rating on Moderna (MRNA)

Tyler Van Buren

TD Cowen

$25

Hold

2.75%

Upside

Reiterated

10/23/25

TD Cowen Remains a Hold on Moderna (MRNA)with no changes to our $25 price target and Hold (2) rating.

Geoff Meacham

Citi

$30→$28

Hold

15.08%

Upside

Reiterated

10/23/25

Moderna's Hold Rating: Impact of CMVictory Study and Vaccine Program Risks

Mani Foroohar

Leerink Partners

$16→$12

Sell

-50.68%

Downside

Reiterated

10/23/25

Moderna (MRNA) Receives a Sell from Leerink PartnersWe reduce our PT to $12 (from $16) and reiterate an Underperform rating.

David Dai

UBS

$40

Buy

64.41%

Upside

Reiterated

10/23/25

Optimistic Outlook on Moderna's Oncology Pipeline Amid CMV Setbacks: Buy Rating Reiterated

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Moderna

1 Month

xxx

Success Rate

28/46 ratings generated profit

Average Return

+0.76%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.87% of your transactions generating a profit, with an average return of +0.76% per trade.

3 Months

xxx

Success Rate

28/46 ratings generated profit

Average Return

-5.65%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of -5.65% per trade.

1 Year

Mani ForooharLeerink Partners

Success Rate

35/46 ratings generated profit

Average Return

-2.11%

reiterated a sell rating 16 days ago

Copying Mani Foroohar's trades and holding each position for 1 Year would result in 76.09% of your transactions generating a profit, with an average return of -2.11% per trade.

2 Years

xxx

Success Rate

39/46 ratings generated profit

Average Return

+30.99%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.78% of your transactions generating a profit, with an average return of +30.99% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRNA Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRNA has received 7 Buy Ratings, 35 Hold Ratings, and 5 Sell Ratings. MRNA average Analyst price target in the past 3 months is 40.06.

Each month's total comprises the sum of three months' worth of ratings.

MRNA Financial Forecast

MRNA Earnings Forecast

Next quarter’s earnings estimate for MRNA is -$2.67 with a range of -$3.53 to -$2.07. The previous quarter’s EPS was -$0.51. MRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year MRNA has Preformed in-line its overall industry.

MRNA Sales Forecast

Next quarter’s sales forecast for MRNA is $702.43M with a range of $540.00M to $945.00M. The previous quarter’s sales results were $1.02B. MRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year MRNA has Preformed in-line its overall industry.

MRNA Stock Forecast FAQ

What is MRNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Moderna’s 12-month average price target is 40.06.

What is MRNA’s upside potential, based on the analysts’ average price target?

Moderna has 64.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRNA a Buy, Sell or Hold?

Moderna has a consensus rating of Hold which is based on 3 buy ratings, 13 hold ratings and 4 sell ratings.

What is Moderna’s price target?

The average price target for Moderna is 40.06. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $198.00 ,the lowest forecast is $12.00. The average price target represents 64.65% Increase from the current price of $24.33.

What do analysts say about Moderna?

Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of MRNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Moderna (MRNA) Stock Forecast & Price Target

MRNA Analyst Ratings

MRNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Moderna

MRNA Analyst Recommendation Trends

MRNA Financial Forecast

MRNA Earnings Forecast

MRNA Sales Forecast

MRNA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts